Your activity: 2 p.v.

Oral isotretinoin therapy for acne vulgaris

Oral isotretinoin therapy for acne vulgaris
Author:
Cindy Owen, MD
Section Editors:
Robert P Dellavalle, MD, PhD, MSPH
Moise L Levy, MD
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor:
Abena O Ofori, MD
Literature review current through: Nov 2022. | This topic last updated: Oct 04, 2022.

INTRODUCTION — Oral isotretinoin (13-cis retinoic acid) is a retinoid most often used for the treatment of acne vulgaris, particularly severe or recalcitrant disease. Isotretinoin is teratogenic and associated with a number of other adverse effects that can limit its use. Thus, it must be used with caution and should only be prescribed by clinicians who are completely familiar with the medication.

The clinical use of oral isotretinoin for acne vulgaris will be reviewed here. Discussions of the clinical manifestations, diagnosis, and approach to treatment for acne vulgaris as well as detailed drug information on isotretinoin are provided separately.

(See "Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris".)

(See "Acne vulgaris: Overview of management".)

(See "Acne vulgaris: Management of moderate to severe acne in adolescents and adults".)

(See "Postadolescent acne in women".)

(See "Acne in infants, young children, and preadolescents".)

(See "Management of acne scars".)

(See "Isotretinoin: Drug information".)

(See "Isotretinoin: Pediatric drug information".)

MECHANISM OF ACTION — Oral isotretinoin counteracts the pathogenic factors that contribute to the development of acne vulgaris [1,2]. Therapy leads to shrinkage of sebaceous glands and a marked attenuation of sebum secretion. The decrease in sebum results in the inhibition of the sebum-dependent bacterium Cutibacterium (formerly Propionibacterium) acnes, which is a key promoter of inflammation in acne vulgaris. Direct anti-inflammatory effects of oral isotretinoin may occur through normalization of the toll-like receptor 2-mediated innate immune response to C. acnes [3]. Oral isotretinoin also inhibits comedogenesis by fostering keratinocyte differentiation and by normalizing desquamation. (See "Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Pathogenesis'.)

ADVERSE EFFECTS — Isotretinoin is a teratogenic drug that is associated with a broad range of mucocutaneous and extracutaneous adverse effects. Side effects of isotretinoin are usually manageable, permitting continuation of therapy. In a 2018 systematic review of 11 randomized trials, severe adverse events requiring withdrawal from trials occurred in only 12 of 372 patients taking isotretinoin (3 percent). The severe adverse events included Stevens-Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches, and depressed mood [4].

The management of common side effects is reviewed below. (See 'Management of complications' below.)

Mucocutaneous — The common mucocutaneous side effects of isotretinoin, including cheilitis, dry skin and mucous membranes, epistaxis, desquamation, photosensitivity, and pruritus, are predictable and dose dependent. In the systematic review, dermatologic side effects represented nearly 65 percent of all reported side effects, with cheilitis and xerosis as the most frequent [4].

Isotretinoin is also associated with risk for ocular abnormalities (eg, dryness, irritation, conjunctivitis) related to dysfunction of meibomian glands within the conjunctiva [4-6]. Cutaneous staphylococcal infections may also occur [7]. Paronychia, pyogenic granulomas, temporary diffuse alopecia, and nail brittleness occasionally appear [8].

Transient worsening of acne may occur in the beginning of isotretinoin therapy. Rarely, isotretinoin induces acne fulminans, a severe manifestation [9,10]. (See 'Severe acne' below.)

Teratogenicity — Isotretinoin causes severe, life-threatening, congenital malformations and spontaneous abortions [11]. Embryopathy associated with exposure in the first trimester of pregnancy includes craniofacial, cardiac, thymic, and central nervous system malformations [12]. Fetal abnormalities have not been attributed to the use of isotretinoin in men [2]. (See "Birth defects: Causes", section on 'Drug exposure'.)

Among pregnant women exposed to isotretinoin, the risk of spontaneous abortion is approximately 20 percent; among pregnancies that progress, approximately 20 to 30 percent of neonates have evidence of embryopathy [13]. Although data are limited, children who appear physically normal may still have a higher rate of intellectual disability and impaired neuropsychologic function [13].

Psychiatric effects — Concerns have been raised about a possible association of isotretinoin with depression and suicide. However, reviews, including a systematic review and meta-analysis, have concluded that data on suicidal behavior and depression during treatment with isotretinoin are inadequate to establish a causal relationship [14-18].

Some authors have proposed that psychologic distress over severe acne, rather than isotretinoin, could be a contributing factor to suicide or depression in patients treated with the drug [19-21]. In a population-based cohort study, risk for major depressive disorder was higher among patients with acne than in the general population without acne [20]. The risk was unchanged after excluding patients who received isotretinoin. (See "Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis".)

In sum, the relationship between isotretinoin and depression and suicide is uncertain. Patients should be advised of a possible link and should be followed closely for the development of depression or suicidal ideation [22]. (See "Suicidal ideation and behavior in adults" and "Suicidal ideation and behavior in children and adolescents: Evaluation and management".)

Inflammatory bowel disease — Although observational studies have found conflicting results on the relationship between isotretinoin therapy and inflammatory bowel disease (IBD), analysis of the available data suggests that isotretinoin therapy is not a risk factor for IBD. A 2012 meta-analysis of three case-control studies and two additional unpublished studies did not find a statistically significant relationship between isotretinoin therapy and IBD (relative risk for IBD 0.94, 95% CI 0.65-1.36) [23].

In addition, a subsequent 12-year cohort study of 46,922 patients treated with isotretinoin, 184,824 patients treated with topical acne medication, and 1,526,946 untreated controls (all between the ages of 12 and 29) did not find a significant association between isotretinoin use and IBD on primary analysis (rate ratio 1.14, 95% CI 0.92-1.41) [24]. Although an association between isotretinoin and IBD was detected in a subgroup of patients aged 12 to 19 years (rate ratio 1.39, 95% CI 1.03-1.87), a similar association was detected between the use of topical acne medications and ulcerative colitis (rate ratio 1.19, 95% CI 1.00-1.42), suggesting that there is an association between acne and IBD independent of treatment.

More studies are necessary to confirm whether isotretinoin therapy is a risk factor for IBD. Until additional information is available, during discussions of the potential adverse effects of isotretinoin with patients, it is reasonable to mention that although an increased risk for IBD has been reported, a relationship between these disorders has not been proven.

Hyperlipidemia — Isotretinoin has been associated with a number of other side effects [4]. Hypertriglyceridemia is common, occurring in up to 45 percent of patients taking isotretinoin, and total cholesterol and low-density lipoprotein elevations occur in approximately 30 percent [25]. The development of hyperlipidemia during isotretinoin therapy may be associated with increased risk for future development of hyperlipidemia and metabolic syndrome [26]. (See 'Laboratory abnormalities' below.)

Other side effects — Other less common side effects include myalgias (particularly in patients who engage in vigorous physical activity), visual changes (decreased night vision, corneal opacities), hepatotoxicity, bone marrow suppression, idiopathic intracranial hypertension (pseudotumor cerebri), and bone changes (hyperostosis and, rarely, premature epiphyseal closure) [27-31]. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Medications'.)

For additional information on isotretinoin side effects, refer to the Lexicomp drug information monograph included within UpToDate. (See "Isotretinoin: Drug information".)

CONTRAINDICATIONS AND PRECAUTIONS

Contraindications — Isotretinoin should not be given to pregnant individuals or individuals who may become pregnant during or within one month after therapy. Effective measures to prevent pregnancy are indicated for all individuals who could become pregnant. Also, individuals with a history of hypersensitivity to isotretinoin or any of its components should not receive isotretinoin. Isotretinoin capsules contain soybean oil and should be used with caution in patients with severe soy allergy.

Drug interactions — Simultaneous treatment with medications that share the side effect of idiopathic intracranial hypertension with isotretinoin, such as tetracyclines, should be avoided. In addition, vitamin A supplementation may increase the adverse effects of isotretinoin and should be avoided. A list of additional drug interactions is provided separately. (See "Isotretinoin: Drug information".)

Specific interactions of isotretinoin with other medications may be determined using the Lexicomp drug interactions tool (Lexi-Interact) included in UpToDate. This tool can also be accessed from the UpToDate online search page or through the individual drug information topics (also referred to as monographs) in the section on Drug interactions.

Children — The effectiveness and safety of isotretinoin has not been established in children under 12 years of age.

Cutaneous procedures — Delaying cutaneous procedures until at least six months after the completion of oral isotretinoin therapy has been historically practiced due to concern for increased risk for abnormal scarring and delayed wound healing. However, the available data suggest that this may not be necessary for some procedures.

Based upon a systematic review of the literature, a multispecialty panel of experts found insufficient evidence to recommend delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients with current or recent isotretinoin use [32]. The panel recommended avoidance of mechanical dermabrasion and fully ablative laser procedures in patients with recent isotretinoin use based upon limited evidence suggesting increased risk for scarring. A task force from the American Society for Dermatologic Surgery (ASDS) reached similar conclusions, with the exception of specifying that while focal or superficial manual dermabrasion does not appear to be associated with increased risk for scarring or delayed wound healing, full-face manual dermabrasion is not recommended within six months after isotretinoin therapy [33].

Although prospective, controlled trials are necessary to confirm the level of risk associated with cutaneous procedures in this population, the findings of the systematic review and ASDS task force aid in counseling patients who may benefit from earlier performance of procedures.

Alcohol use — Although alcohol consumption is not contraindicated during isotretinoin therapy, we generally counsel patients to avoid excessive alcohol consumption. Similar to isotretinoin, alcohol consumption may contribute to hypertriglyceridemia and hepatic transaminase elevations. Moreover, excessive alcohol consumption may contribute to impaired judgment and substandard use of pregnancy prevention methods and has negative effects on overall health. (See "Overview of the risks and benefits of alcohol consumption".)

INITIATION OF THERAPY — The initiation of isotretinoin therapy involves careful patient counseling and a pretreatment clinical and laboratory assessment. The goal is to support successful treatment and minimize risk for serious adverse effects. (See 'Patient counseling' below and 'Baseline clinical and laboratory evaluation' below and 'Dosing and administration' below and 'Use of other acne medications' below.)

Patient counseling — In addition to a discussion of the risks and benefits of treatment, patients who will begin isotretinoin therapy should be thoroughly informed of the monitoring and pregnancy prevention measures that are required for isotretinoin therapy. Some countries have implemented mandatory risk management programs designed to prevent fetal exposure to isotretinoin, though positive effects of such programs on reducing fetal exposure are unproven [34].

In the United States, prescribing and receipt of isotretinoin requires participation in the iPLEDGE program. The iPLEDGE program provides detailed guidelines for pregnancy prevention counseling, pregnancy screening, and contraceptive use during treatment. (See 'iPLEDGE program' below.)

In general, prescribing clinicians should be able to discuss contraceptive options and appropriate use with patients of childbearing potential. Alternatively, these patients should be referred to a provider who can provide this service. All patients who are at risk for pregnancy during treatment should begin highly effective contraceptive measures one month prior to, during, and for one month after completion of isotretinoin therapy. In addition, patients should avoid sharing isotretinoin pills with others and should avoid blood donation during therapy and for one month after completion of therapy.

A discussion of the ocular side effects of isotretinoin may be particularly important for patients in occupations with strict guidelines for vision, such as airline pilots. In the United States, the Federal Aviation Administration has policies regarding isotretinoin therapy.

iPLEDGE program — In 2006, the US Food and Drug Administration (FDA) established a computer-based Risk Evaluation and Mitigation Strategy (REMS) risk management program with the goal of eliminating fetal exposure to isotretinoin (iPLEDGE). Prescribers, pharmacies dispensing isotretinoin, wholesalers distributing isotretinoin, and all patients receiving isotretinoin are required to comply with the registry requirements.

Access to the iPLEDGE program is available online. The iPLEDGE program requires the following [35]:

All patients who can get pregnant must select and commit to the use of two forms of birth control for at least one month prior to starting isotretinoin therapy, during therapy, and for one month after therapy. The forms of contraception that meet these requirements are specified by the iPLEDGE program.

All patients who can get pregnant must have two negative urine or blood pregnancy tests (with a sensitivity of at least 25 milli-international units/mL) before receiving the initial prescription. The second pregnancy test must be conducted in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. For each month of therapy and one month after completing therapy, patients must return to their clinicians for evaluation, counseling, education, and a pregnancy test conducted by a CLIA-certified laboratory.

For patients who can get pregnant, prescribing clinicians must, on a monthly basis, document in the iPLEDGE system the results of the pregnancy test as well as report the two forms of birth control being used by the patient. The clinician must also confirm that the patient has received counseling and education. For all other patients, prescribers must document that the patient was counseled on the iPLEDGE program requirements, which include knowledge of the birth defects that may result from the use of isotretinoin by individuals of childbearing potential.

As part of this system, clinicians must certify expertise in the diagnosis and treatment of acne, and knowledge of the risk and severity of birth defects with isotretinoin.

Baseline clinical and laboratory evaluation — The pretreatment clinical and laboratory evaluation serves to identify patients who are not candidates for isotretinoin therapy (eg, pregnant individuals) and patients who may require closer monitoring during therapy. Examples of patients for whom additional counseling or monitoring may be helpful include patients with [2]:

Prior contraceptive failure

History of uncontrolled depression or suicidal ideation

Hyperlipidemia or family history of early-onset hyperlipidemia

Personal or family history of inflammatory bowel disease

Eye or vision problems (particularly dry eyes and contact lens use)

Heavy alcohol use

Extreme physical activity

Current medications should be reviewed to identify potential drug interactions. In particular, treatment with other drugs that may cause pseudotumor cerebri, such as tetracyclines, should be avoided. (See 'Drug interactions' above.)

Baseline laboratory testing is indicated to identify pregnant patients and patients with liver or lipid abnormalities. In the past, obtaining full liver function, lipid, and complete blood count panels in addition to a urine or serum pregnancy test for individuals who could become pregnant was common. However, the need for this extent of testing in healthy patients has been questioned [36]. (See 'Laboratory monitoring' below.)

Our typical pretreatment tests include:

Alanine aminotransferase (ALT) and triglyceride levels within one month prior to the start of therapy

Urine or serum pregnancy test in individuals of childbearing potential (note that two tests are required prior to the start of therapy for the iPLEDGE program) (see 'iPLEDGE program' above)

Dosing and administration — Absorption of isotretinoin is improved when taken with food (especially high-fat meals); thus, administration during meals is recommended. A formulation of isotretinoin that uses lipid encapsulation technology to enclose isotretinoin demonstrates increased bioavailability in the fasting state [37]. This formulation is dosed twice daily and can be given without regard to meals.

Severe acne — Severe acne is considered acne with many inflammatory nodules or other severe features (eg, extensive involvement of one or more body regions with comedonal or papulopustular acne) (picture 1A-F). The treatment goal for these patients is a cumulative dose of 120 to 150 mg/kg of isotretinoin to decrease the risk of acne recurrence [31]. Most patients achieve this goal within 20 to 24 weeks.

Treatment is usually initiated at a dose of 0.5 mg/kg per day for the first month of therapy to minimize risk for isotretinoin-induced acne flares and is subsequently increased to 1 mg/kg per day. The total daily dose of isotretinoin is typically divided in two doses taken with food; alternatively, isotretinoin can be taken once daily to increase adherence to therapy.

Isotretinoin-induced acne flaring or acne fulminans may occur at the start of isotretinoin therapy in patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) or deep comedonal acne. Starting doses lower than 0.5 mg/kg per day are suggested for this population. In addition, systemic glucocorticoids may be given prior to the start of isotretinoin or concurrently for the first two to four weeks. (See "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne conglobata' and "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'.)

There is some evidence that high cumulative doses (eg, ≥220 mg/kg) of isotretinoin may reduce the risk of relapse in patients with severe acne vulgaris [38,39]. Additional studies are needed to confirm this finding as well as the safety of high-dose isotretinoin therapy.

Moderate acne — Moderate acne appropriate for isotretinoin therapy may be considered less extensive acne that is treatment resistant, relapses rapidly after cessation of oral antibiotic therapy, scars, or induces significant psychosocial distress (picture 2) [31]. Patients with moderate acne are usually treated with a regimen identical to that used for severe acne, achieving a cumulative dose of 120 to 150 mg/kg over the course of 20 to 24 weeks.

However, a lower-dose regimen (0.3 to 0.5 mg/kg per day for the duration of therapy) may be an alternative [31,40]. The advantage of this lower dose is reduced risk for drug side effects [31].

A 24-week, single-blind, randomized trial in which 60 patients with moderate acne were treated with one of three regimens of isotretinoin, 0.5 to 0.7 mg/kg per day (higher-dose regimen), 0.25 to 0.4 mg/kg per day (lower-dose regimen), or 0.5 to 0.7 mg/kg daily for one week every four weeks (intermittent regimen), supports efficacy of lower-dose therapy [41]. All three treatment courses resulted in clinically significant improvement and marked reductions in mean acne lesion counts. The lower-dose and higher-dose regimens were similarly effective and had equivalent rates of relapse after one year; however, more adverse effects were reported in the higher-dose group during treatment. A lesser degree of improvement and a lower duration of effect were detected in the patients who received intermittent therapy.

Use of other acne medications — Other acne medications are typically discontinued at the start of isotretinoin therapy. Isotretinoin causes temporary xerosis, cutaneous atrophy, and skin fragility, and topical acne medications may be poorly tolerated [2]. Isotretinoin should not be given with tetracyclines due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri) associated with both of these drugs.

DURING THERAPY — Follow-up visits are typically held on a monthly basis to assess response and side effects, address patient questions, and fulfill the counseling and monitoring requirements of the iPLEDGE program.

Clinical assessment — Patient assessment should include a patient history and skin examination to assess for response and adverse effects. We typically ask the patient about the following:

Perceived worsening/improvement of acne

Dryness of skin or mucous membranes

Nosebleeds

Vision changes

Headaches

Abdominal pain

Joint, muscle, or bone pain

Bowel symptoms

Mood changes, symptoms of depression, or suicidality

We examine involved skin as well as any other areas of concern for the patient. In our experience, signs of improvement in acne often become evident after the first one to two months of therapy, with progressive improvement over subsequent months.

Laboratory monitoring — Laboratory monitoring during isotretinoin therapy generally consists of assessments for pregnancy, liver dysfunction, and dyslipidemia. Baseline and post-treatment testing are reviewed separately. (See 'Baseline clinical and laboratory evaluation' above and 'Follow-up' below.)

Test selection and frequency — Historically, monthly checking of full liver function and lipid panels during isotretinoin treatment was a routine and well-accepted practice. However, in otherwise healthy, asymptomatic, young individuals without a personal or family history of diabetes or dyslipidemia, there are data that suggest it may be safe to perform less extensive and less frequent testing. (See 'Evidence' below.)

Monitoring of complete blood count panels is not necessary in the absence of a known abnormality or risk factor for leukopenia. There are differing opinions on the need for monitoring creatine kinase levels. In general, obtaining a creatine kinase level is not indicated in the absence of severe muscular pain [2].

Our approach to laboratory monitoring during isotretinoin therapy is as follows [42] (see 'Baseline clinical and laboratory evaluation' above):

Monthly pregnancy tests in individuals who can become pregnant. (See 'iPLEDGE program' above.)

If baseline alanine aminotransferase (ALT) and triglyceride levels were normal, these tests should be repeated after the peak isotretinoin dose is reached (we typically obtain these tests one month after starting the peak dose, which is usually after completion of a total of two months of isotretinoin therapy).

If the results of testing after reaching the peak dose are normal and the dose of isotretinoin is not increased, then further monitoring is not required. If the results of testing are abnormal or if the patient has a known lipid abnormality, then periodic monitoring should be continued.

Development of new symptoms (eg, abdominal pain), the initiation of new medications or supplements, or an increase in the dose of isotretinoin may warrant retesting.

Evidence — Examples of studies suggesting that a more limited approach to laboratory testing in healthy patients is reasonable include:

The findings of a systematic review and meta-analysis of studies reporting laboratory values during isotretinoin therapy for acne support less frequent testing; although isotretinoin was associated with statistically significant changes in the mean values of some laboratory tests (white blood cell count, hepatic panel, lipid panel), the changes did not meet criteria for high risk, and the proportion of patients with laboratory abnormalities was low [43].

In a retrospective study of 903 patients treated with isotretinoin for acne vulgaris, no clinically significant hematologic abnormalities were detected during treatment [44]. Although patients experiencing elevation of triglyceride levels (n = 197), ALT (n = 113), and aspartate aminotransferase (AST; n = 102) were common, all but seven cases of triglyceride, ALT, or AST elevation were successfully managed with observation or lowering of the isotretinoin dose, and all elevations resolved after completion of isotretinoin.

A Delphi consensus study that involved the administration of four rounds of anonymous surveys on isotretinoin laboratory monitoring to a group of 22 international acne experts provides additional support [36]. Tests evaluated included the components of liver function, basal metabolic, lipid, and complete blood count panels, as well as creatine kinase and C-reactive protein levels. Consensus was defined by agreement among ≥70 percent of participants.

Interventions that met consensus criteria included obtaining ALT and triglyceride levels within one month prior to initiation of isotretinoin and after reaching peak dose. There was consensus that the following were not necessary: obtaining ALT or triglyceride levels monthly or after completion of isotretinoin therapy; obtaining complete blood count or basal metabolic panels at any point during treatment; and checking gamma-glutamyl transferase, bilirubin, albumin, total protein, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or C-reactive protein levels at any point during treatment. There was no consensus on practices for checking AST, alkaline phosphatase, creatine kinase, and total cholesterol levels.

Management of complications — Most of the adverse effects associated with isotretinoin can be managed without discontinuing the drug.

Exacerbation of acne — Transient worsening of acne may occur during the first month of treatment, particularly in patients with severe disease (see 'Severe acne' above). Significant flares may require adjustments to therapeutic approach. For mild flares, no adjustment in treatment is needed.

The approach to isotretinoin-induced acne fulminans is reviewed separately (picture 3 and algorithm 1). (See "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'.)

Mucocutaneous — Dry skin and mucous membranes are common during treatment. In particular, cheilitis can be significant and often requires the liberal use of topical emollients, such as petroleum jelly or other lip moisturizers.

To minimize dry skin, patients are advised to wash with a gentle, nondetergent cleanser followed by the application of emollients. A noncomedogenic emollient is recommended for acne-prone skin areas. (See "Treatment of atopic dermatitis (eczema)", section on 'Emollients and moisturizers'.)

For patients with nasal crusting or dryness or with epistaxis, saline nasal spray and application of petroleum jelly to the nostrils can be helpful. Artificial tears may help to reduce symptoms of eye dryness. Patients who wear contact lenses may not be able to tolerate them during treatment and may need to discontinue their use.  

Sun-protective measures are indicated to minimize the effects of isotretinoin-induced photosensitivity. Patients should use a facial moisturizer with a sun protection factor (SPF) of at least 30 daily, and sun-protective clothing should be worn during sun exposure. Sunscreen should be applied to exposed skin areas prior to sun exposure and reapplied every two to three hours. (See "Selection of sunscreen and sun-protective measures".)

Myalgias — Although checking of creatine kinase (CK) levels is not indicated in the absence of severe muscle pain, CK levels are elevated in approximately 15 to 50 percent of patients with isotretinoin-induced myalgias [2]. Mild to moderate pain usually can be managed with anti-inflammatory drugs. Isotretinoin should be discontinued if pain becomes severe or cannot be improved with anti-inflammatory drugs [2].

Laboratory abnormalities — Hypertriglyceridemia, hepatic transaminase elevations, and CK elevations are common laboratory abnormalities during isotretinoin treatment:

Hypertriglyceridemia – Minor or moderate elevations in triglyceride levels (300 to 500 mg/dL) do not necessitate alteration of the isotretinoin dose and can be managed with lifestyle modification [45]. (See "Hypertriglyceridemia in adults: Management", section on 'Moderate hypertriglyceridemia'.)

Triglyceride levels between 500 and 800 mg/dL require additional intervention, such as reduction of the dose of isotretinoin and/or the addition of a lipid-lowering agent [45]. (See "Hypertriglyceridemia in adults: Management", section on 'Treatment goals'.)

Severe hypertriglyceridemia (eg, above 800 mg/dL) may warrant cessation of isotretinoin therapy because of the risk of acute pancreatitis [45,46]. However, pancreatitis secondary to isotretinoin is rare [47].

Although hypertriglyceridemia usually resolves with cessation of isotretinoin, patients may need ongoing monitoring since one report suggests that they may be at increased risk for future hyperlipidemia and metabolic syndrome [26]. In a cross-sectional study, 102 patients in whom the serum triglyceride concentration increased at least 89 mg/dL (1 mmol/L) during isotretinoin therapy (hyper-responders) were compared with 100 patients in whom the serum triglyceride concentration changed ≤9 mg/dL (0.1 mmol/L, nonresponders). Four years after completion of isotretinoin therapy, hyper-responders were significantly more likely to have hypertriglyceridemia (odds ratio [OR] 4.8, 95% CI 1.6-13.8), hypercholesterolemia (OR 9.1, 95% CI 1.9-43), truncal obesity (OR 11.0, 95% CI 2.0-59), and hyperinsulinemia (OR 3.0, 95% CI 1.6-5.7).

Hepatic transaminase elevations – Mild, transient elevations in hepatic transaminases occur early in the course of therapy in approximately 15 to 20 percent of patients; levels typically normalize within a few weeks [2]. Discontinuation of isotretinoin is recommended if hepatic transaminase levels reach more than three times greater than normal values [2,48].

Pregnancy — Despite efforts to minimize risk for pregnancy during isotretinoin therapy, such as mandatory participation in the iPLEDGE program in the United States, pregnancies still occur [49]. If pregnancy occurs during treatment, isotretinoin should be stopped immediately. The pregnant patient should be referred to an obstetrician-gynecologist with experience in reproductive toxicity for management and counseling [50]. In the United States, the iPLEDGE program requires reporting of pregnancies that occur during therapy.

Other — The management of other extracutaneous adverse effects of isotretinoin (eg, psychiatric effects, severe eye symptoms), may warrant consultation with appropriate specialists to determine the best course of action for individual patients. Patients with signs and symptoms suggestive of pseudotumor cerebri (eg, headache with new-onset vision changes) require specialist evaluation and should discontinue use of isotretinoin. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis" and "Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment".)

STOPPING THERAPY — In patients treated for severe acne, isotretinoin is usually discontinued after achievement of the goal cumulative dose of 120 to 150 mg/kg and acne clearance. The drug can be stopped abruptly; tapering is not necessary.

AFTER THERAPY

Outcomes — Oral isotretinoin is the only acne medication that can permanently alter the natural course of the disorder. The majority of patients experience long-term improvement in acne severity after one course of treatment [51]. In addition, continued improvement may occur for several months after cessation of therapy; thus, at least five months should elapse before considering retreatment with isotretinoin.

Response rates after a second course of isotretinoin are similar to those following the initial course of treatment [48].

Reported relapse rates for patients treated with 120 to 150 mg/kg of isotretinoin range between 20 and 60 percent [38]. In one study of 88 patients treated with isotretinoin for severe or refractory acne and followed for up to 10 years, 82 percent of patients who received cumulative doses <120 mg/kg relapsed (defined as deterioration in acne sufficient to merit systemic antibiotic or isotretinoin therapy), compared with only 20 percent of patients given >120 mg/kg [51]. Most relapses (78 percent) occurred within the first 18 months after treatment. Patients with truncal acne relapsed more frequently than patients with predominantly facial acne (40 versus 20 percent).

In addition to cumulative dose <120 to 150 mg/kg in patients with severe acne and presence of truncal acne, additional risk factors for relapse include male gender, young age at time of isotretinoin initiation (<16 years of age), postadolescent females with acne, females with polycystic ovary syndrome, and females not receiving antiandrogen therapy [52,53].

Patients who receive isotretinoin as young teenagers (under age 16) may also have an increased risk for relapse [54].

Follow-up — Individuals of childbearing potential require a final pregnancy test one month after completion of isotretinoin. We counsel patients to return for re-evaluation if acne recurs. Patients with scarring may benefit from referral to a clinician with expertise in the treatment of acne scars. (See "Management of acne scars".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Acne vulgaris" and "Society guideline links: COVID-19 – Index of guideline topics".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Acne (The Basics)")

Beyond the Basics topics (see "Patient education: Acne (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Mechanism of actionIsotretinoin is a treatment for acne vulgaris that is thought to improve acne through reducing sebum production, inhibiting the growth of Cutibacterium (formerly Propionibacterium) acnes, inhibiting comedogenesis, and altering the inflammatory response. (See 'Mechanism of action' above.)

Adverse effectsIsotretinoin has multiple side effects, including teratogenicity, mucocutaneous disorders, myalgias, visual changes, idiopathic intracranial hypertension, hepatotoxicity, and hyperlipidemia. (See 'Adverse effects' above.)

Isotretinoin is teratogenic and should not be administered in pregnancy. In the United States, all prescribing clinicians and patients are required to participate in the iPLEDGE program, an online registry initiated by the US Food and Drug Administration (FDA) in an attempt to minimize the risk of fetal exposure to isotretinoin. (See 'Teratogenicity' above and 'Patient counseling' above and 'iPLEDGE program' above.)

Dosing and administration:

General approach – For the treatment of severe acne, isotretinoin is typically started at a low dose (0.5 mg/kg per day) during the first month of therapy and then increased to 1 mg/kg per day. A total dose of 120 to 150 mg/kg of isotretinoin is given over the course of treatment. The duration of treatment is often between 20 and 24 weeks or until acne is clear. (See 'Dosing and administration' above.)

Other acne medications are typically discontinued during isotretinoin therapy. In particular, the use of isotretinoin with tetracyclines should be avoided due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri). (See 'Drug interactions' above and 'Use of other acne medications' above.)

Acne conglobata and acne fulminans – Patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) may require a lower initial dose and/or concomitant treatment with systemic glucocorticoids starting before or at the initiation of oral isotretinoin therapy. (See 'Severe acne' above and "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne conglobata' and "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'.)

Outcomes – Most patients improve after isotretinoin therapy, although the majority of patients will continue to require the use of other acne therapies. Continued improvement may occur for several months after isotretinoin therapy; therefore, subsequent courses of isotretinoin should not be initiated until at least five months after completion of the previous treatment period. (See 'Outcomes' above.)

  1. Ward A, Brogden RN, Heel RC, et al. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28:6.
  2. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197.
  3. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132:2198.
  4. Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 2018; 178:76.
  5. Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol 2012; 148:803.
  6. Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286.
  7. Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987; 123:606.
  8. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150.
  9. López-Vílchez MA, Vicente Villa MA, García-Fructuoso MT, et al. [Acne fulminans after the treatment with isotretinoin]. An Esp Pediatr 1999; 51:200.
  10. Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.
  11. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837.
  12. Centers for Disease Control and Prevention (CDC). Accutane-exposed pregnancies--California, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:28.
  13. Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143:1187.
  14. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005; 24:92.
  15. Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55:134.
  16. Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23:665.
  17. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol 2008; 144:1197.
  18. Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 76:1068.
  19. Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011; 131:363.
  20. Vallerand IA, Lewinson RT, Parsons LM, et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol 2018; 178:e194.
  21. Sundström A, Alfredsson L, Sjölin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341:c5812.
  22. www.fda.gov/cder/drug/InfoSheets/HCP/IsotretinoinHCP.htm (Accessed on August 12, 2005).
  23. Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol 2013; 149:216.
  24. Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133:907.
  25. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142:1016.
  26. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136:582.
  27. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176.
  28. Steele RG, Lugg P, Richardson M. Premature epiphyseal closure secondary to single-course vitamin A therapy. Aust N Z J Surg 1999; 69:825.
  29. Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. Joint Bone Spine 2012; 79:314.
  30. Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 1982; 7:663.
  31. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.
  32. Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol 2017; 153:802.
  33. Waldman A, Bolotin D, Arndt KA, et al. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg 2017; 43:1249.
  34. Kovitwanichkanont T, Driscoll T. A comparative review of the isotretinoin pregnancy risk management programs across four continents. Int J Dermatol 2018; 57:1035.
  35. www.ipledgeprogram.com (Accessed on April 23, 2009).
  36. Xia E, Han J, Faletsky A, et al. Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol 2022; 158:942.
  37. Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 2013; 69:762.
  38. Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149:1392.
  39. Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51:1123.
  40. Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev 2018; 11:CD009435.
  41. Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164:1369.
  42. Hansen TJ, Lucking S, Miller JJ, et al. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol 2016; 75:323.
  43. Lee YH, Scharnitz TP, Muscat J, et al. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. JAMA Dermatol 2016; 152:35.
  44. Shah R, Kroshinsky D. Re-evaluating the need for routine laboratory monitoring in patients taking isotretinoin: A retrospective analysis. J Am Acad Dermatol 2021; 85:504.
  45. Patton TJ, Ferris LK. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 3rd ed, Wolverton SE (Ed), Elsevier, 2013. p.262.
  46. McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87:1855.
  47. Opel D, Kramer ON, Chevalier M, et al. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol 2017; 177:960.
  48. Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.275.
  49. Tkachenko E, Singer S, Sharma P, et al. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin. JAMA Dermatol 2019; 155:1175.
  50. https://www.ipledgeprogram.com/iPledgeUI/rems/pdf/resources/Prescriber%20Isotretinoin%20Educational%20Kit.pdf (Accessed on January 18, 2019).
  51. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292.
  52. Morales-Cardona CA, Sánchez-Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr 2013; 104:61.
  53. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136:66.
  54. Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157:1240.
Topic 38 Version 33.0

References